Creso Pharma’s target acquisition company announces expansion into other psychedelic compounds
Finfeed
Archived
Apr 12, 2021
Creso Pharma Limited (ASX: CPH, FRA:1X8) has provided an update regarding target acquisition company, Halucenex Life Sciences, outlining its entry into an advisory agreement with Growing Together Research Inc. (GTR) to explore the genome sequencing of natural psilocybe.